KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresLong-Term Debt RepaymentsNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rigel Pharmaceuticals (RIGL) Change in Receivables (2016 - 2025)

Rigel Pharmaceuticals (RIGL) has 11 years of Change in Receivables data on record, last reported at $5.8 million in Q4 2025.

  • For Q4 2025, Change in Receivables fell 47.12% year-over-year to $5.8 million; the TTM value through Dec 2025 reached $10.1 million, down 8.29%, while the annual FY2025 figure was $10.1 million, 8.29% down from the prior year.
  • Change in Receivables reached $5.8 million in Q4 2025 per RIGL's latest filing, down from $6.0 million in the prior quarter.
  • Across five years, Change in Receivables topped out at $126.2 million in Q1 2021 and bottomed at -$124.8 million in Q2 2021.
  • Average Change in Receivables over 5 years is $1.8 million, with a median of $936500.0 recorded in 2021.
  • The widest YoY moves for Change in Receivables: up 28087.14% in 2021, down 6138.85% in 2021.
  • A 5-year view of Change in Receivables shows it stood at $481000.0 in 2021, then soared by 5054.89% to $24.8 million in 2022, then tumbled by 71.75% to $7.0 million in 2023, then soared by 57.62% to $11.0 million in 2024, then tumbled by 47.12% to $5.8 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Receivables were $5.8 million in Q4 2025, $6.0 million in Q3 2025, and -$1.6 million in Q2 2025.